NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit
01 März 2024 - 10:04PM
NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or
“NurExone”), a pioneering biopharmaceutical company, is pleased to
announce that Dr. Ina Sarel, the Head of CMC, Quality and
Regulatory Affairs at NurExone, will be leading a workshop at the
upcoming Exosome Characterization & Analytical Development
Summit. Dr. Sarel will be sharing with her expert colleagues
insight and information on the topic of "Regulatory Challenges in
the Development of an Extracellular Vesicles (EVs) - Based Clinical
Product."
Dr. Sarel joins a prestigious lineup of speakers
including representatives from leading exosome companies, e.g.
AbbVie, RION Therapeutics, Aegle Therapeutics and universities,
e.g. Harvard Medical school. With her experience in regulatory
affairs and her deep understanding of the exosome field, Dr. Sarel
is well-positioned to provide perspective on how to navigate the
complex regulatory landscape and ensure the successful development
of exosome-based therapeutics.
Dr. Sarel who led the activities that resulted
in the grant of Orphan Drug Designation for ExoPTEN, an
exosome-therapy being developed by the Company, stated “NurExone is
developing a platform for using exosomes to create wide range of
nanodrugs including our first drug - ExoPTEN, for treating patients
with acute spinal cord injury. We are proud to share our
development outcomes together with our regulatory expertise and are
committed to advancing the field of exosome therapeutics for
clinical use.”
The Exosome Characterization & Analytical
Development Summit is a premier event that brings together experts
from academia and industry to discuss the latest advancements in
exosome characterization and analytical development. The summit
will take place on April 23-25, 2024 in Boston, MA. To learn more
about the summit and to register, please visit the Conference
Website.
About NurExone Biologic
Inc.
NurExone Biologic Inc. is a TSXV listed
pharmaceutical company that is developing a platform for
biologically-guided exosome-based therapies to be delivered,
non-invasively, to patients who have suffered Central Nervous
System injuries. The company’s first product, ExoPTEN for acute
spinal cord injury, was proven to recover motor function in 75% of
laboratory rats when administered intranasally. ExoPTEN has been
granted Orphan Drug Designation bythe FDA. The NurExone platform
technology is expected to offer novel solutions to drug companies
interested in noninvasive targeted drug delivery for other
indications.
For additional information, please visit
www.nurexone.com or follow NurExone on LinkedIn, Twitter, Facebook,
or YouTube.
For more information, please contact:
Dr. Lior ShaltielChief Executive Officer and DirectorPhone:
+972-52-4803034Email: info@nurexone.com
Thesis Capital Inc.Investment Relation - CanadaPhone: +1
905-347-5569Email: IR@nurexone.com
Dr. Eva ReuterInvestment Relation - GermanyPhone:
+49-69-1532-5857Email: e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
This press release contains certain
forward-looking statements, including statements about the
Company's future plans and intellectual property, the scientific
and development and commercial activities to be carried out by the
company, the efficient loading of exosomes, future potential
manufacturing, clinical, licensing and marketing activities and the
treatment of certain conditions. Wherever possible, words such as
"may", "will", "should", "could", "expect", "plan", "intend",
"anticipate", "believe", "estimate", "predict" or "potential" or
the negative or other variations of these words, or similar words
or phrases, have been used to identify these forward-looking
statements. These statements reflect management's current beliefs
and are based on information currently available to management as
at the date hereof. Forward-looking statements involve significant
risk, uncertainties and assumptions. Many factors could cause
actual results, performance or achievements to differ materially
from the results discussed or implied in the forward-looking
statements. Certain assumptions include the ability of the Company
to commercialize its intellectual property internally and through
licensing and that the Company has the appropriate team in order to
realize commercialization. Risks and uncertainties include, but are
not limited to, risks related to the Company's early stage of
development, lack of revenues to date, government regulation,
market acceptance for its products, rapid technological change,
dependence on key personnel, protection of the Company's
intellectual property and dependence on the Company's strategic
partners. These factors should be considered carefully and readers
should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in this press
release are based upon what management believes to be reasonable
assumptions, the Company cannot assure readers that actual results
will be consistent with these forward-looking statements. These
forward-looking statements are made as of the date of this press
release, and the Company assumes no obligation to update or revise
them to reflect new events or circumstances, except as required by
law.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Nurexone Biologic (TSXV:NRX)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Nurexone Biologic (TSXV:NRX)
Historical Stock Chart
Von Sep 2023 bis Sep 2024